Skip to main content
Premium Trial:

Request an Annual Quote

Eyeing Chinese IVD Market, OriGene Buys BioCheck

Premium

OriGene Technologies said this week that it has acquired Foster City, Calif.-based immunoassay firm BioCheck.

The acquisition expands Origene's in vitro diagnostic portfolio and capabilities for future product development, the company said. In particular, the purchase provides OriGene with IVD products for the Chinese clinical market, currently a major area of focus for the company.

According to OriGene, the Chinese IVD market is among the fastest growing in the world and is predicted to be the second largest globally by 2017.

"OriGene values BioCheck’s unique combination of novel [US Food and Drug Administration-cleared] diagnostic products and its custom immunoassay development platform," OriGene CEO Wei-Wu He said in a statement. "Gaining such capacity is crucial to OriGene’s mission to empower the Chinese IVD market with more specific and sensitive products for responsive decision making and improved health outcomes."

BioCheck has developed custom immunoassays for a variety of conditions, including colorectal cancer, breast cancer, osteoporosis, heart disease, and several infectious diseases.

The price of the acquisition and other terms of the deal were not disclosed.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.